Dr. Wierda Discusses Use of CAR T Cells in CLL


William G. Wierda, MD, PhD, discusses how CAR T cells could become more effective in the treatment of patients with chronic lymphocytic leukemia.

William G. Wierda, MD, PhD, associate professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses how chimeric antigen receptor (CAR) T cells could become more effective in the treatment of patients with chronic lymphocytic leukemia (CLL).

Early data for CAR T-cell therapies in these patients have been shown to elicit lower remission rate of around 30% compared with the 80% remission rate seen in acute lymphoblastic leukemia. However, Wierda says recent findings of research conducted by University of Pennsylvania group demonstrated that T cells collected from patients who were on ibrutinib (Imbruvica) treatment had a higher potency. Ibrutinib is associated with immune-modulating effects that could lead to better outcomes in these patients with CLL.

Related Videos
Daniel Hart, PhD, on CRISPR-Mediated, In Vivo Epigenomic Activation
Luke Roberts, MBBS, PhD, on Developing Gene Therapy for Congestive Heart Failure
PJ Brooks, PhD, on Improved Newborn Screening, Non-Viral Gene Editing: New Frontiers for Neuromuscular Disease
Sowmya Viswanathan, PhD, on Translating Cell Therapies to the Clinic at ISCT 2024
Omar Nadeem, MD, on Initial Efficacy of GPRC5D-CAR in R/R Multiple Myeloma
Omer A. Abdul Hamid, MD, on Improving Gene Therapy’s Effect and Accessibility
George Tachas, PhD, on Tackling DMD Treatment From Multiple Angles
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
Jeffrey Chamberlain, PhD, on Helping Progress Cell and Gene Therapy Development
© 2024 MJH Life Sciences

All rights reserved.